<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000438729"><TermName>IMMU-106</TermName><TermDefinition><DefinitionText>A substance being studied in the treatment of several types of lymphoma. It binds to the protein CD20, which is found on B cells (a type of immune system cell) and some types of lymphoma cells. This causes the immune system to kill the cancer cells. IMMU-106 is a type of monoclonal antibody. Also called hA20, HCD20,  and veltuzumab.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><SpanishTermName>IMMU-106</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de varios tipos de linfoma. Se une a la proteína CD20, que se encuentra en las células B (tipo de célula del sistema inmunitario) y a algunos tipos de células de linfomas. Hace que el sistema inmunitario destruya las células cancerosas. IMMU-106 es un tipo de anticuerpo monoclonal. También se llama hA20, HCD20,  y veltuzumab.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2005-08-24</DateFirstPublished><DateLastModified>2010-04-07</DateLastModified></GlossaryTerm>
